December 7, 2020 -- The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses, bringing the total order commitment to 40 million doses.
Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted this month. The company has already initiated the rolling regulatory approval process with Health Canada and intends to seek prequalification and/or emergency use listing with the World Health Organization. The Canadian vaccine supply will be sourced from Moderna's European production capacity with its strategic manufacturing partner in Switzerland, Lonza, and its fill/finish partner in Spain, ROVI.
On November 30, Moderna announced the primary efficacy analysis of its phase III study of mRNA-1273, indicating a 94.1% efficacy rate.